Hot Atara snags licensing deal with cancer center
Experimental off-the-shelf cell therapies against cancer and long-term viral infections were grabbed by Atara Biotherapeutics Inc. in a licensing deal with Memorial Sloan Kettering Cancer Center.
South San Francisco's Atara (NASDAQ: ATRA) — part of the San Francisco Business Times' life sciences IPO Class of 2014 — said Monday that it licensed three programs already in clinical trials that boost the body's ability to fight Epstein Barr Virus, or EBV, cytomegalovirus and Wilms Tumor 1, or WT1.…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Cytomegalovirus | Health | Health Management | Pharmaceuticals | Wilm's Tumor